AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Neural stem/progenitor cell transplantation therapy for chronic spinal cord injury

Jun Zhanga,b, Xiaolong Zhengb,c( ), Zitao Wud, Yu Wanga,b( ), Hong Chenb,e,f( )
Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China
Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China
Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China
Department of Electrical and Computer Engineering, University of Illinois Urbana- Champaign, Urbana 61801, IL, USA
Department of Rehabilitation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China
Stem Cell Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China
Show Author Information

Abstract

Spinal cord injury (SCI) is a severely disabling neurological condition that results in impaired mobility, sensory disruption, and autonomic dysfunction. Transplantation of neural stem/progenitor cells (NSPCs) is considered a promising candidate for promoting functional recovery, and most research has focused on the early stages of SCI. However, most SCI patients are in the chronic phase, and clinical trials for patients with chronic SCI will be able to detect additional potential treatment effects. Therefore, this review focuses on the study of advances in the transplantation of NSPCs obtained or derived from different sources for chronic SCI. We first summarize the progress in the use of rodent NSPC transplantation for chronic SCI. Rodent NSPCs can survive, differentiate, and support histological regeneration at the site of injury but only with cellular combination therapy can they induce functional motor recovery. Next, we review research advances in human NSPC transplantation alone or in combination therapies for chronic SCI, demonstrating a high potential therapeutic effect. Finally, we discuss clinical trials of human NSPC transplantation for chronic SCI, focusing on safety and feasibility as the main clinical outcome measures. The long-term follow-up data also show optimistic clinical therapeutic efficacy.

References

【1】
【1】
 
 
Journal of Neurorestoratology

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Zhang J, Zheng X, Wu Z, et al. Neural stem/progenitor cell transplantation therapy for chronic spinal cord injury. Journal of Neurorestoratology, 2025, 13(5). https://doi.org/10.1016/j.jnrt.2025.100223

4195

Views

7

Crossref

5

Web of Science

7

Scopus

Received: 21 December 2024
Revised: 20 February 2025
Accepted: 10 April 2025
Published: 01 October 2025
© 2025 The Authors.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).